| P50 | author | Corinne Faivre-Finn | Q37830473 |
| | Matthias Guckenberger | Q40544777 |
| | Emad Shash | Q42689893 |
| | Rafal Dziadziuszko | Q58328150 |
| P2093 | author name string | C Le Pechoux | |
| | U Nestle | |
| | C Fink | |
| | S Collette | |
| | D De Ruysscher | |
| | M Lambrecht | |
| | S Adebahr | |
| | C Hurkmans | |
| | H Peulen | |
| | J Belderbos | |
| P2860 | cites work | Global cancer statistics | Q22241238 |
| | The tumor radiobiology of SRS and SBRT: are more than the 5 Rs involved? | Q26823489 |
| | Surgical and nonsurgical approaches to small-size nonsmall cell lung cancer | Q26825694 |
| | Outcomes of stereotactic ablative radiotherapy for central lung tumours: a systematic review | Q27012449 |
| | Phase I study of accelerated conformal radiotherapy for stage I non-small-cell lung cancer in patients with pulmonary dysfunction: CALGB 39904. | Q33627751 |
| | CyberKnife radiosurgery for inoperable stage IA non-small cell lung cancer: 18F-fluorodeoxyglucose positron emission tomography/computed tomography serial tumor response assessment | Q33698367 |
| | No clinically significant changes in pulmonary function following stereotactic body radiation therapy for early- stage peripheral non-small cell lung cancer: an analysis of RTOG 0236 | Q33758565 |
| | Which is the optimal biologically effective dose of stereotactic body radiotherapy for Stage I non-small-cell lung cancer? A meta-analysis | Q33928404 |
| | Stereotactic body radiotherapy for lung tumors at the pulmonary hilum | Q84146368 |
| | Central-airway necrosis after stereotactic body-radiation therapy | Q84368705 |
| | Stereotactic ablative radiotherapy (SABR) using 70 Gy in 10 fractions for non-small cell lung cancer: exploration of clinical indications | Q87536544 |
| | Toxicities of organs at risk in the mediastinal and hilar regions following stereotactic body radiotherapy for centrally located lung tumors | Q87575211 |
| | Stereotactic body radiation therapy for inoperable early stage lung cancer | Q34010065 |
| | Outcome of four-dimensional stereotactic radiotherapy for centrally located lung tumors | Q34135022 |
| | Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable). | Q34202691 |
| | CyberKnife for hilar lung tumors: report of clinical response and toxicity | Q34331400 |
| | Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer | Q34575077 |
| | Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group | Q34721402 |
| | Local control and toxicity in a large cohort of central lung tumors treated with stereotactic body radiation therapy | Q34771688 |
| | Tolerance of organs at risk in small-volume, hypofractionated, image-guided radiotherapy for primary and metastatic lung cancers. | Q35106919 |
| | Effect of comorbidity on the treatment and prognosis of elderly patients with non-small cell lung cancer | Q35536822 |
| | Predictors of radiotherapy induced bone injury (RIBI) after stereotactic lung radiotherapy. | Q36500564 |
| | Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). | Q36943220 |
| | Possible misinterpretation of demarcated solid patterns of radiation fibrosis on CT scans as tumor recurrence in patients receiving hypofractionated stereotactic radiotherapy for lung cancer | Q36955637 |
| | Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials | Q37047747 |
| | Results of initial low-dose computed tomographic screening for lung cancer | Q37146277 |
| | Dose-limiting toxicity after hypofractionated dose-escalated radiotherapy in non-small-cell lung cancer | Q37333649 |
| | Definition of stereotactic body radiotherapy: principles and practice for the treatment of stage I non-small cell lung cancer | Q37468265 |
| | Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up | Q37489156 |
| | Radiation dose-volume effects in the spinal cord. | Q37695551 |
| | Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery? | Q37773607 |
| | CyberKnife Stereotactic Ablative Radiotherapy for Lung Tumors | Q37808696 |
| | Stereotactic body radiation therapy for thoracic cancers: recommendations for patient selection, setup and therapy | Q37882372 |
| | Radiographic changes after lung stereotactic ablative radiotherapy (SABR)--can we distinguish recurrence from fibrosis? A systematic review of the literature | Q37981413 |
| | EORTC Radiation Oncology Group quality assurance platform: establishment of a digital central review facility | Q38013439 |
| | Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines | Q38104632 |
| | Esophageal dose tolerance to hypofractionated stereotactic body radiation therapy: risk factors for late toxicity | Q38228512 |
| | Global harmonization of quality assurance naming conventions in radiation therapy clinical trials | Q38300232 |
| | Prospective, risk-adapted strategy of stereotactic body radiotherapy for early-stage non-small-cell lung cancer: results of a Phase II trial | Q39847699 |
| | What is the current status of Stereotactic body radiotherapy for stage I non-small cell lung cancer? | Q40342856 |
| | Radiotherapy alone for medically inoperable stage I non-small-cell lung cancer: the Duke experience | Q41677591 |
| | Applicability of the linear-quadratic formalism for modeling local tumor control probability in high dose per fraction stereotactic body radiotherapy for early stage non-small cell lung cancer. | Q43445849 |
| | Withholding stereotactic radiotherapy in elderly patients with stage I non-small cell lung cancer and co-existing COPD is not justified: outcomes of a Markov model analysis | Q43638703 |
| | Stereotactic ablative radiotherapy for small lung tumors with a moderate dose. Favorable results and low toxicity | Q44020055 |
| | Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer | Q44377522 |
| | Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: a population-based time-trend analysis | Q44592987 |
| | Early-stage lung cancer in elderly patients: a population-based study of changes in treatment patterns and survival in the Netherlands | Q44961453 |
| | Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame | Q45157055 |
| | Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. | Q45794075 |
| | Natural history of stage I non-small cell lung cancer: implications for early detection | Q46506976 |
| | Steep dose-response relationship for stage I non-small-cell lung cancer using hypofractionated high-dose irradiation by real-time tumor-tracking radiotherapy | Q48895589 |
| | Safety and efficacy of stereotactic body radiotherapy for stage 1 non-small-cell lung cancer in routine clinical practice: a patterns-of-care and outcome analysis. | Q50736160 |
| | Stereotactic body radiotherapy for cardiac and paracardiac metastases: University of Florence experience. | Q50851277 |
| | Brachial plexopathy from stereotactic body radiotherapy in early-stage NSCLC: dose-limiting toxicity in apical tumor sites. | Q51829460 |
| | Estimation of tumor control probability model parameters from 3-D dose distributions of non-small cell lung cancer patients. | Q52209578 |
| | Stereotactic body radiotherapy for centrally located stage I NSCLC: a multicenter analysis. | Q53054421 |
| | Outcomes of stereotactic ablative radiotherapy following a clinical diagnosis of stage I NSCLC: comparison with a contemporaneous cohort with pathologically proven disease. | Q53090898 |
| | Stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer. | Q53299557 |
| | Fractionated stereotactic body radiation therapy for medically inoperable stage I lung cancer adjacent to central large bronchus. | Q53518246 |
| | Comparing different NTCP models that predict the incidence of radiation pneumonitis | Q57619609 |
| | Outcomes of Stereotactic Ablative Radiotherapy in Patients With Potentially Operable Stage I Non-Small Cell Lung Cancer | Q59587407 |
| | Outcomes of Stereotactic Ablative Radiotherapy for Centrally Located Early-Stage Lung Cancer | Q59587430 |
| | Stage I nonsmall cell lung cancer in patients aged ≥75 years | Q59587510 |
| | A modified hypoxia-based TCP model to investigate the clinical outcome of stereotactic hypofractionated regimes for early stage non-small-cell lung cancer (NSCLC) | Q60393653 |
| | Radiation pneumonitis in patients treated for malignant pulmonary lesions with hypofractionated radiation therapy | Q61183008 |
| | Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms | Q62007533 |
| | Radiotherapy alone in technically operable, medically inoperable, early-stage (I/II) non-small-cell lung cancer | Q74619608 |
| | Dose, volume, and tumor control prediction in primary radiotherapy of non-small-cell lung cancer | Q77711995 |
| | Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: relevance of 4D dose calculation | Q79769691 |
| | Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study | Q80587769 |
| | Bronchovascular versus bronchial sleeve resection for central lung tumors | Q81588673 |
| | Mature results of an individualized radiation dose prescription study based on normal tissue constraints in stages I to III non-small-cell lung cancer | Q82833722 |
| | Local extension at the hilum region is associated with worse long-term survival in stage I non-small cell lung cancers | Q83153456 |
| | Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study | Q83405180 |
| | Central thoracic lesions treated with hypofractionated stereotactic body radiotherapy | Q83575603 |
| | Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy | Q83768631 |
| | Stereotactic body radiation therapy for early stage non-small cell lung cancer: results of a prospective trial | Q84127941 |
| P433 | issue | 1051 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | adaptive radiation therapy | Q180507 |
| | phase II clinical trial | Q42824440 |
| P304 | page(s) | 20150036 | |
| P577 | publication date | 2015-04-15 | |
| P1433 | published in | British Journal of Radiology | Q15758529 |
| P1476 | title | LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective | |
| P478 | volume | 88 | |